Reduced expression of E-cadherin/catenin complex in hepatocellular carcinomas

Figure 1 Immunoreactivity of E-cadherin, α- and β-catenins in HCCs. A and B: Stained for E-cadherin: preserved type (+), reduced type (-); C-E: Stained for α-catenin: preserved type (+), reduced type (-) and staining in the cytoplasm; F-I: Stained for β-catenin: preserved type (+), reduced type (-) and staining in the cytoplasm and the nucleus (× 200).

Figure 2 Immunoreactivity of γ-catenin and p120 in HCCs. A-C: Stained for γ-catenin: preserved type (+), reduced type (-) and staining in the cytoplasm; D-F: Stained for p120: preserved type (+), reduced type (-) and staining in the cytoplasm (× 200).

Figure 3 Kaplan-Meier survival curves with normal (pink line) or abnormal (green line), A: Expression of E-cadherin (P = 0. 0253); B: Expression of α-catenin (P = 0.0052); C: Expression of β-catenin (P = 0.003); D: Expression of γ-catenin (P = 0.0105); E: Expression of p120 (P = 0.0016). Abnormal expressions of E-cadherin/catenin complex significantly related with poor survival.